利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

489 条记录 (耗时 0.018 秒)

    METHOD FOR PRODUCING DISPERSION OF RUTILE-TYPE TITANIUM OXIDE PARTICLES
    3.
    发明公开
    METHOD FOR PRODUCING DISPERSION OF RUTILE-TYPE TITANIUM OXIDE PARTICLES 有权
    制造方法分散体金红石二氧化钛

    公开(公告)号：EP2607318A1

    公开(公告)日：2013-06-26

    申请号：EP11818261.7

    申请日：2011-08-15

    申请人： Sakai Chemical Industry Co., Ltd.

    发明人： MORITA Takanori ,  NAKAGAWA Kenichi ,  NOMURA Atsushi

    IPC分类号： C01G23/053 ,  C08K3/20 ,  C08L101/00 ,  C09D17/00

    CPC分类号： B01J31/38 ,  C01G23/047 ,  C01G23/0536 ,  C01P2002/52 ,  C01P2002/54 ,  C01P2002/72 ,  C01P2004/51 ,  C01P2004/62 ,  C01P2006/12 ,  C08L101/00 ,  C09C1/3607 ,  C09D17/008 ,  G02B1/04

    摘要： The invention provides a process for producing an aqueous dispersion of particles of rutile titanium oxide, which comprises:
    a first step in which after a chloride ion concentration of an aqueous solution of titanium tetrachloride is adjusted to 0.5 mole/L or more and less than 4.4 mole/L, the aqueous solution of titanium tetrachloride is heated at a temperature in a range of from 25°C to 75 °C to hydrolyze the titanium tetrachloride, thereby obtaining a slurry containing the thus precipitated particles of rutile titanium oxide;
    a second step in which the slurry obtained in the first step is filtered and washed with water to remove water-soluble salts dissolved therein from the slurry;
    a third step in which the slurry obtained in the second step is subjected to a hydrothermal reaction in the presence of an organic acid;
    a fourth step in which the slurry obtained in the third step is filtered and washed with water to remove water-soluble salts dissolved therein from the slurry;
    a fifth step in which an acid is added to the slurry obtained in the fourth step to deflocculate the slurry, and the resulting slurry is subjected to wet dispersion treatment, thereby obtaining a dispersion; and
    a sixth step in which excess acid and water-soluble salts are removed from the dispersion obtained in the fifth step.

    Nitrogeneous heterocyclic derivative and medicine containing the same as an active ingredient
    4.
    发明公开
    Nitrogeneous heterocyclic derivative and medicine containing the same as an active ingredient 审中-公开
    Stickstoffhaltige hybridlische Derivate und Medizin damit als ein Wirkstoff

    公开(公告)号：EP2546234A1

    公开(公告)日：2013-01-16

    申请号：EP12186689.1

    申请日：2005-09-12

    申请人： ONO PHARMACEUTICAL CO., LTD.

    发明人： Takaoka, Yoshikazu ,  Shibayama, Shiro ,  Nishizawa, Rena

    IPC分类号： C07D211/58 ,  A61K31/444 ,  A61K31/4468 ,  A61K45/00 ,  A61P11/06 ,  A61P29/00 ,  A61P31/04 ,  A61P31/18 ,  A61P37/00 ,  A61P37/06 ,  A61P43/00

    CPC分类号： C07D413/12 ,  A61K31/00 ,  C07D211/58 ,  C07D231/12 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D409/14

    摘要： Compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof:

    (wherein the characters are as defined in the description). The compounds of the general formula (I) have a CCR5 antagonistic activity, so that they are useful in the prevention and/or therapy for CCR5 mediated diseases, for example, various inflammatory diseases (asthma, gastritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis and other inflammatory intestinal failure, etc.), immunologic diseases (autoimmune disease, rejection of transplanted organ (rejection of solid organ transplant graft, rejection of pancreatic islet cell transplant in diabetes, graft-versus-host disease, etc.), immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (human immunodeficiency virus infection, acquired immunodeficiency syndrome, RSV infection, etc.) allergoses (atopic dermatitis, hives, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), cardiovascular risks (arteriosclerosis suppression of ischemic reperfusion injury, etc.), acute respiratory distress syndrome, shock caused by bacterial infection, diabetes, cancer metastasis, etc.

    摘要翻译： 通式（I）的化合物，其盐和N-氧化物及其溶剂合物和前药：（其中字符如说明书中所定义）。 通式（I）的化合物具有CCR5拮抗活性，因此它们可用于预防和/或治疗CCR5介导的疾病，例如各种炎性疾病（哮喘，胃炎，肾病，肝炎，关节炎，类风湿病 关节炎，鼻炎，结膜炎，溃疡性结肠炎和其他炎性肠衰竭等），免疫疾病（自身免疫性疾病，移植器官的排斥反应（实体器官移植移植排斥反应，糖尿病胰岛细胞移植排斥反应，移植物抗宿主 疾病等），感染性疾病（人类免疫缺陷病毒感染，获得性免疫缺陷综合征，RSV感染等）变态反应（特应性皮炎，荨麻疹，过敏性支气管肺曲霉病，过敏嗜酸性肠胃炎， 等等），心血管风险（动脉硬化抑制缺血再灌注损伤等），急性呼吸道分泌物 ess综合征，细菌感染引起的休克，糖尿病，癌转移等